bimatoprost/brimonidine/timolol / AbbVie - LARVOL DELTA

Fixed-combination Bimatoprost/Brimonidine/Timolol in Glaucoma: A Randomized, Masked, Controlled, Phase III Study Conducted in Brazil. (PubMed, Clin Ther) - P3 | "Compared with DFC, TFC provided superior IOP lowering throughout the primary efficacy period. An acceptable tolerability profile was observed through 12 months of use of TFC, offering an effective therapeutic option in patients with POAG or OHT who require multiple medications to control their IOP. Additional studies are required for the assessment of the long-term effects of TFC. ClinicalTrials.gov identifier: NCT01217606."

Clinical • Journal • P3 data • Glaucoma • Hypertension • Ophthalmology

[VIRTUAL] Severe Limbal Stem Cell Deficiency and Cicatricial Conjunctivitis Secondary to Preserved Glaucoma Eyedrops (ASCRS-ASOA 2020) - "The patient was using brinzolamide, bimatoprost, and brimonidine-timolol...Results All eyedrops were stopped, and the patient was started on non-preserved dorzolamide-timolol and tafluprost...BAK disrupts cells, which is responsible not only for its antimicrobial actions, but also its toxicity. Management involves removal of the offending agent and monitoring for progression."

Cataract • Conjunctivitis • Dermatology • Dermatopathology • Glaucoma • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology

Drugs for common eye disorders. (PubMed, Med Lett Drugs Ther) - No abstract available.

Journal • Review

Effect of topical hypotensive medications for preventing intraocular pressure increase after cataract surgery in eyes with glaucoma (Am J Ophthalmol) - P=NA, N=165; "Brinzolamide more effectively reduces the short-term IOP increase after cataract surgery compared with travoprost or timolol in eyes with glaucoma, suggesting that brinzolamide is preferable for preventing an IOP spike."

Clinical data

12-MONTH EFFICACY AND SAFETY OF BRIMONIDINE TARTRATE 0.2%/TIMOLOL 0.5% OPHTHALMIC SOLUTION IN KOREAN PATIENTS WITH PRIMARY OPEN-ANGLE AND NORMAL-TENSION GLAUCOMA–THE KOCO STUDY (COPHy AA 2019) - "Purpose: Efficacy and safety of fixed-combination brimonidine 0.2%/timolol 0.5% (FCBT) alone or with bimatoprost 0.01% (BIM) were assessed over 12 months in Korean patients with primary open-angle glaucoma (POAG) and normal-tension glaucoma (NTG). Despite mean baseline IOP of 16.8 mmHg, ≥20% IOP reduction persisted over 12 months in patients with POAG/ NTG receiving FCBT or FCBT+BIM, without significant mean change in MD. Ocular TEAEs mirrored reported drug safety profiles."

Clinical